Assembly Biosciences, Inc.

ASMBNASDAQHealthcare● Active

$22.56

$-0.35(-1.51%)

Market Cap$358464382

P/E Ratio—

52W High$39.71

52W Low$15.71

Avg Volume131K

Open$23.47

Beta1.08

Free Cash Flow Financials Revenue

Assembly Biosciences, Inc. (ASMB) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ASMB · free cash flow · updated Jun 9, 2026

Core FCF metrics

ASMB · FCF · TTM · margin & CAGR

Free cash flow was −$41.2M for FY2025 (fiscal year ending 2025-12-31), up 19.5% year-over-year The FCF margin was -56.9%.

FY2025 Free Cash Flow−$41.2M▲ +19.5% YoY

Trailing 12M (TTM)−$39.8Mtrailing 4 quarters sum

FCF Margin-56.9%−$41.2M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ASMB · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$41.1M(0M)−$41.2M▲ +19.5%-56.9%

FY2024−$51.1M(0M)−$51.1M▼ 327.4%-179.3%

FY2023$22.7M(0M)$22.5M▲ +126.6%313.9%

FY2022−$84.5M(0M)−$84.6M▲ +12.4%—

FY2021−$93.4M(3M)−$96.5M▼ 48.0%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ASMB · P/FCF · FCF yield · FCF per share

Assembly Biosciences, Inc. (ASMB) reported negative free cash flow of −$0.04B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ASMB · cash flow statement · operating / investing / financing

For FY2025, Assembly Biosciences, Inc. generated −$41.1M in operating cash flow and spent 0M in capital expenditures, yielding −$41.2M in free cash flow.

Operating Activities

−$41.1M

Cash from core business operations

2025-12-31

Investing Activities

−$113.5M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$174.7M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$41.1M) − |CapEx| (0M) = FCF (−$41.2M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ASMB vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Assembly Biosciences, Inc.YOU

ASMB

−$41.2M+19.5%-56.9%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Assembly Biosciences, Inc. (ASMB) reported free cash flow of −$41.2M for FY2025 (fiscal year ending 2025-12-31), up 19.5% year-over-year. The FCF margin was -56.9%.

Based on available data, Assembly Biosciences, Inc. has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $22.5M in FY2023.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ASMB free cash flow · 8 questions

Assembly Biosciences, Inc. free cash flow was −$41.2M for FY2025, up 19.5% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$39.8M.

ASMB free cash flowASMB FCFASMB FCF 2025ASMB free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Assembly Biosciences, Inc. · Assembly Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026